Exelixis, Inc. Hits New 52-Week High of $55.88, Soars 145%

Exelixis, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 55.88 on June 29, 2026. This achievement underscores the company's robust performance, with a remarkable one-year return of 145.28%, significantly outpacing the S&P 500's 20.53% return during the same period. The company boasts a market capitalization of USD 10,786 million and maintains a price-to-earnings (P/E) ratio of 14.00, reflecting its strong earnings potential. Exelixis has demonstrated impressive financial health, with a return on equity (ROE) of 36.94% and a net profit growth of 31.86%. The firm has also reported positive results for three consecutive quarters, showcasing its consistent operational strength. Additionally, Exelixis is net-debt free, further enhancing its financial stability. With a price-to-book ratio of 4.99, the stock is trading at a premium compared to historical valuations of its peers. The company's strong fundamentals and high institutional holdings at 100% indicate a solid market position, contributing to its recent performance and milestone achievement.